Cargando…

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma

Detalles Bibliográficos
Autores principales:	Romano, Alessandra, Scandura, Grazia, Santuccio, Gabriella, Puglisi, Fabrizio, Cambria, Daniela, Amorini, Angela Maria, La Spina, Enrico, Parrinello, Nunziatina Laura, Giallongo, Cesarina, Tibullo, Daniele, Cerchione, Claudio, Martinelli, Giovanni, Simonetti, Giorgia, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Genomics, Biology & Microenvironment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642056/ http://dx.doi.org/10.1097/01.HS9.0000890736.04861.d9

Ejemplares similares

P1288: ALTERED AMINO ACID HOMEOSTASIS CAN ELICIT AN ADAPTIVE RESPONSE VIA UPREGULATION OF UFMYLATION IN HODGKIN LYMPHOMA
por: Romano, A., et al.
Publicado: (2022)

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
por: Romano, Alessandra, et al.
Publicado: (2022)

P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
por: Romano, A., et al.
Publicado: (2023)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
por: La Spina, Enrico, et al.
Publicado: (2023)

P870: DEFINING A NOVEL FUNCTION FOR THE POST-TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA
por: Romano, A., et al.
Publicado: (2022)

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
por: Giallongo, Cesarina, et al.
Publicado: (2020)

P01: ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY.
por: Romano, A, et al.
Publicado: (2022)

TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
por: Scandura, Grazia, et al.
Publicado: (2022)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA
por: Giallongo, C., et al.
Publicado: (2023)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia
por: Mussai, Francis, et al.
Publicado: (2019)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells
por: Vetro, Calogero, et al.
Publicado: (2015)

P043: Molecular pathogenesis of Hodgkin lymphoma
por: Beeck, Lilian, et al.
Publicado: (2022)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
por: Kilian, Annika L., et al.
Publicado: (2022)

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2022)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

P040: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
por: Wadel, Annika, et al.
Publicado: (2022)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
por: Fromm, Jonathan, et al.
Publicado: (2022)

PB2534: SARS-COV-2 IMMUNIZATION AFTER VACCINES IN PATIENTS WITH HEMOGLOBINOPATHY: A SINGLE CENTER EXPERIENCE
por: Duminuco, Andrea, et al.
Publicado: (2023)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hk7c9uqemjtdepcdmt7tssmrs3